Medicine · 2026
Application of high-flux hemodialysis combined with hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of renal anemia in patients with uremia: A randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Jiajia, Gong Anming, Lin Yurun, Zhang Chengjuan, Guo Jiguang
Аннотация
BACKGROUND: This study aimed to explore the efficacy of combining high‑flux hemodialysis (HFHD) with a hypoxia‑inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of renal anemia among patients with end-stage kidney disease.
METHODS: Sixty-four newly treated maintenance hemodialysis (MHD) patients were allocated to 4 groups (n = 16 each): low-flux hemodialysis (LFHD) plus recombinant human erythropoietin (rhEPO), LFHD plus HIF-PHI, HFHD plus rhEPO, and HFHD plus HIF‑PHI. All patients underwent hemodialysis 3 times per week, each session lasting 4 hours. After 2 months of treatment, we measured and compared changes in hemoglobin (HB), red blood cells (RBC), hepcidin, total iron‑binding capacity (TIBC), ferritin, transferrin saturation (TSAT), parathyroid hormone (PTH), and β2-microglobulin (β2-MG), along with the incidence of adverse events in each group.
RESULTS: All groups showed increases in HB and RBC post‑treatment (P <.05). The increases in hemoglobin (ΔHB) and RBC (ΔRBC) were significantly greater in the HFHD + HIF-PHI and LFHD + HIF-PHI groups than in the LFHD + rhEPO and HFHD + rhEPO groups. Posttreatment PTH and β2-MG levels were elevated in the LFHD + rhEPO and LFHD + HIF-PHI groups compared with pretreatment (P <.05). Furthermore, posttreatment PTH and β2-MG were lower in the HFHD + HIF-PHI and HFHD + rhEPO groups than in the other 2 groups (P <.05). Posttreatment hepcidin was significantly reduced in the HFHD + HIF-PHI and LFHD + HIF-PHI groups compared to pretreatment. Posttreatment TIBC and TSAT were higher in the HFHD + HIF-PHI and LFHD + HIF-PHI groups than pretreatment (P <.05). The incidence of adverse reactions was numerically lower in the HIF-PHI groups than in the rhEPO group, but the difference was not statistically significant.
CONCLUSION: Compared to low-flux dialysis plus rhEPO, the combination of HFHD and HIF-PHI shows more favorable improvements in hemoglobin levels, iron metabolism markers, and clearance of middle-molecule toxins in patients with incident MHD. However, the safety profile requires further evaluation in larger trials.
METHODS: Sixty-four newly treated maintenance hemodialysis (MHD) patients were allocated to 4 groups (n = 16 each): low-flux hemodialysis (LFHD) plus recombinant human erythropoietin (rhEPO), LFHD plus HIF-PHI, HFHD plus rhEPO, and HFHD plus HIF‑PHI. All patients underwent hemodialysis 3 times per week, each session lasting 4 hours. After 2 months of treatment, we measured and compared changes in hemoglobin (HB), red blood cells (RBC), hepcidin, total iron‑binding capacity (TIBC), ferritin, transferrin saturation (TSAT), parathyroid hormone (PTH), and β2-microglobulin (β2-MG), along with the incidence of adverse events in each group.
RESULTS: All groups showed increases in HB and RBC post‑treatment (P <.05). The increases in hemoglobin (ΔHB) and RBC (ΔRBC) were significantly greater in the HFHD + HIF-PHI and LFHD + HIF-PHI groups than in the LFHD + rhEPO and HFHD + rhEPO groups. Posttreatment PTH and β2-MG levels were elevated in the LFHD + rhEPO and LFHD + HIF-PHI groups compared with pretreatment (P <.05). Furthermore, posttreatment PTH and β2-MG were lower in the HFHD + HIF-PHI and HFHD + rhEPO groups than in the other 2 groups (P <.05). Posttreatment hepcidin was significantly reduced in the HFHD + HIF-PHI and LFHD + HIF-PHI groups compared to pretreatment. Posttreatment TIBC and TSAT were higher in the HFHD + HIF-PHI and LFHD + HIF-PHI groups than pretreatment (P <.05). The incidence of adverse reactions was numerically lower in the HIF-PHI groups than in the rhEPO group, but the difference was not statistically significant.
CONCLUSION: Compared to low-flux dialysis plus rhEPO, the combination of HFHD and HIF-PHI shows more favorable improvements in hemoglobin levels, iron metabolism markers, and clearance of middle-molecule toxins in patients with incident MHD. However, the safety profile requires further evaluation in larger trials.